Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion
Hsiang‐Chi Huang,Shih‐Han Wang,Guo‐Chen Fang,Wen‐Cheng Chou,Chun‐Che Liao,Cheng‐Pu Sun,Jia‐Tsrong Jan,Hsiu‐Hua Ma,Hui‐Ying Ko,Yi‐An Ko,Ming‐Tsai Chiang,Jian‐Jong Liang,Chun‐Tse Kuo,Te‐An Lee,Diego Morales‐Scheihing,Chen‐Yang Shen,Shih‐Yu Chen,Louise D. McCullough,Lu Cui,Gerlinde Wernig,Mi‐Hua Tao,Yi‐Ling Lin,Yao‐Ming Chang,Shu‐Ping Wang,Yun‐Ju Lai,Chia‐Wei Li
DOI: https://doi.org/10.1002/jmv.28478
IF: 20.693
2023-01-09
Journal of Medical Virology
Abstract:Patients with severe COVID‐19 often suffer from lymphopenia, which is linked to T cell sequestration, cytokine storm and mortality. However, it remains largely unknown how SARS‐CoV‐2 induces lymphopenia. Here, we studied the transcriptomic profile and epigenomic alterations involved in cytokine production by SARS‐CoV‐2‐infected cells. We adopted a reverse time‐order gene coexpression network (TO‐GCN) approach to analyze time‐series RNA‐sequencing data, revealing epigenetic modifications at the late stage of viral egress. Furthermore, we identified SARS‐CoV‐2‐activated NF‐κB and IRF1 pathways contributing to viral infection and COVID‐19 severity through epigenetic analysis of H3K4me3 ChIP‐sequencing. Cross‐referencing our transcriptomic and epigenomic datasets revealed that coupling NF‐κB and IRF1 pathways mediate PD‐L1 immunosuppressive programs. Interestingly, we observed higher PD‐L1 expression in Omicron‐infected cells than SARS‐CoV‐2 infected cells. Blocking PD‐L1 at an early stage of virally‐infected AAV‐hACE2 mice significantly recovered lymphocyte counts and lowered inflammatory cytokine levels. Our findings indicate that targeting the SARS‐CoV‐2‐mediated NF‐κB and IRF1‐PD‐L1 axis may represent an alternative strategy to reduce COVID‐19 severity. This article is protected by copyright. All rights reserved.
virology